Key Takeaways:
Inventiva raised $120 million in equity and secured €130 million in committed debt financing to fund operations through its pivotal Phase 3 MASH trial readout.
Inventiva removed near-term balance sheet risk Tuesday by raising $120 million in equity and securing €130 million in committed debt financing, extending its cash runway through a pivotal Phase 3 readout for its MASH therapy.
The refinancing positions the clinical-stage biopharmaceutical company to focus on its lead candidate, lanifibranor, for metabolic dysfunction-associated steatohepatitis, Inventiva said in a statement. The deal includes repaying the existing European Investment Bank loan in full and buying back related warrants.
The equity component consists of 27,272,727 American Depositary Shares priced at $4.40 per ADS, raising about $120 million. On the debt side, BlackRock and Claret Capital Partners committed up to €130 million in tranches, subject to conditions, with an initial drawdown of €75 million covering Tranche A and Tranche B. An additional uncommitted tranche of €20 million is available. The company trades on both Euronext Paris and the Nasdaq under the ticker IVA.
For Inventiva, the capital restructuring removes the risk of a dilutive down-round or distressed financing ahead of its most important clinical catalyst. MASH affects an estimated 115 million people globally, and no oral therapies have received FDA approval, making the Phase 3 data a potential inflection point for the company and the broader metabolic disease space.
Cash Runway Through a Binary Catalyst
Inventiva had not disclosed its precise cash position before the deal, but the combined $120 million equity raise and €130 million committed debt facility provide a cushion through the Phase 3 readout and beyond. Biotech companies at this stage typically burn $30 million to $60 million per quarter on late-stage trials, manufacturing, and administrative costs. The financing signals institutional confidence from BlackRock, one of the world's largest asset managers, which structured the debt component alongside Claret Capital Partners.
The equity offering will dilute existing shareholders — the 27.3 million new ADSs represent a significant increase to the company's share count. However, the alternative of running out of cash before the data readout carried far greater downside risk. The $4.40 per ADS offering price reflects a discount to the prior trading price, a common feature of marketed equity offerings.
Competitive Positioning in the MASH Race
Inventiva's lanifibranor, a pan-PPAR agonist, is among a handful of late-stage candidates targeting MASH, a liver disease with no approved oral therapies. Madrigal Pharmaceuticals' Rezdiffra (resmetirom) received accelerated FDA approval in 2024 for MASH with moderate-to-advanced liver fibrosis, becoming the first and only approved therapy. Other competitors include Intercept Pharmaceuticals (obeticholic acid, which faced FDA setbacks) and Akero Therapeutics (efruxifermin, in Phase 2b/3).
Lanifibranor's Phase 2b NATIVE trial showed a 49% rate of MASH resolution without worsening fibrosis, compared with 22% for placebo. The upcoming Phase 3 readout will determine whether those results hold in a larger patient population and whether Inventiva can capture a share of a market projected to exceed $20 billion annually by the early 2030s.
Inventiva shares, trading at about $4.40 per ADS at the offering price, reflect the binary nature of the upcoming catalyst. A positive Phase 3 result could re-rate the stock multiple times higher, while a miss would likely force the company to seek a partner or restructure again. The refinancing buys time for the science to deliver an answer.
This article is for informational purposes only and does not constitute investment advice.
